Rituxan led Medicare part B drug spending in 2014

In 2014, Medicare part B drug spending was led by the $1.5 billion cost of Rituxan (rituximab), the Centers for Medicare & Medicaid Services reported. That made Rituxan – approved to treat...
Source: Rheumatology News - Category: Rheumatology Source Type: research